New Eye Drop Targets Unmet Need in Pterygium Treatment with Dr. Abu Abraham Cloudbreak Pharma

Dr. Abu Abraham, Chief Medical Officer at Cloudbreak Pharma,  discusses the disease burden and gaps in care for patients with Pterygium, also known as Surfer's eye. Pterygium is an ocular surface disorder that creates a growth on the eye's surface that can cause vision problems. The condition is more prevalent in individuals over 40, but it can also affect younger populations exposed to risk factors from spending time outside in the sun and being exposed to UV light. Cloudbreak Pharma is developing CBT-001, an investigational therapy, a multi-kinase inhibitor administered as an eye drop that aims to stop the progression of Pterygium. Abu explains, "Pterygium is a relatively common condition. It's an ocular surface disorder. It's a growth. The word Pterygium derives from the Greek pteryx, which means wedge-shaped. This growth is also a wedge shape that grows from the mucous membrane that overlies the white portion of a person's eye and grows in the direction of the cornea. The cornea itself is a curved structure that's clear, and its function is to focus light or bend light to enter the right way into the eye." "But this can affect anybody who has exposure to UV light. A person working outdoors or even doing a lot of outdoor activities in their free time has the potential to have a Pterygium grow on their eye as one of the triggers. UV light is not the only trigger. There is the potential, possibly, that there are genetic factors. I think they have been identified but may not be fully understood, as well as the genetic factors that contribute to the growth of a Pterygium." #CloudbreakPharma #Pterygium #SurfersEye #OcularDisease #OcularExternalDisease #PatientBurden CloudbreakPharma.com Download the transcript here